Non-FDA-Approved GLP-1 Agonists Remain Available Despite Shortage Resolution

San Diego is often viewed through the lens of its coastline and biotech hubs, but recently, the city became the center of a much more urgent conversation regarding the current state of weight loss medications. Whereas many in the healthcare community believed that the supply chain for GLP-1 receptor agonists had finally stabilized, the reality on the ground tells a different story. During the Obesity Medicine Association’s annual meeting held right here in San Diego, data emerged suggesting that non-FDA-approved versions of these drugs are not only present but remain widely available, even as the official shortages are supposedly resolving.

This proves a bit of a paradox. On one hand, the official word is that the drug shortages are easing. On the other, the market for “off-brand” or compounded alternatives is still thriving. This disconnect creates a complex environment for patients in the San Diego area who are trying to navigate their health journeys. When we talk about these alternatives, we are specifically referring to compounded GLP-1s—medications that aren’t the brand-name versions approved by the FDA, but are instead created through a specific pharmaceutical process.

Understanding the Mechanics of Compounding

To get a handle on why these drugs are still circulating, it helps to understand exactly what “compounding” entails. According to Michael J. DiStefano, PhD, MBE, an assistant professor of pharmaceutical outcomes research at the University of Colorado Anschutz Skaggs School of Pharmacy and Pharmaceutical Sciences, compounding isn’t a one-size-fits-all approach. He explained during his presentation that it is essentially a process where pharmacists or physicians mix or alter the ingredients of a drug. The goal, in a traditional sense, is to produce a medication that meets the specific, individualized needs of a particular patient.

In a perfect world, compounding is a tool for precision medicine—adjusting a dose or removing an allergen for someone who can’t take a standard formulation. However, the surge in GLP-1 demand has shifted the scale. We are no longer just talking about individual patient needs; we are seeing a widespread availability of these copies. This is where the conversation shifts from pharmaceutical flexibility to local healthcare standards and patient safety.

The Safety Gap and the Regulatory Question

The core of the tension lies in the approval process. When a drug is FDA-approved, it has undergone rigorous testing for safety, efficacy and purity. Compounded versions, by their very nature, do not move through this same centralized federal approval process. This has led institutions like the University of Colorado Anschutz to raise critical questions: Are these Ozempic-like copies actually safe?

For residents in San Diego, this question isn’t just academic. It’s a practical concern that affects every clinic visit and pharmacy interaction. The availability of these non-FDA-approved agonists, despite the resolution of shortages, suggests that the appetite for these alternatives remains high. Whether this is due to cost, accessibility, or a lingering distrust in the primary supply chain, the result is a landscape where patients are often choosing between a brand-name drug that may be hard to secure and a compounded version whose long-term safety profile is still being questioned by experts.

The data presented at the Obesity Medicine Association meeting underscores a systemic issue. If the shortage is over, the continued reliance on compounded versions indicates a shift in how these medications are being distributed and perceived. It forces us to look closely at the pharmacy resources available in our community and how transparent the communication is between the provider and the patient regarding the origin of their medication.

Navigating Weight Loss Care in San Diego

Given my background in analyzing these trends, if this shift toward compounded medications impacts you or your family here in San Diego, it is imperative to move beyond generic advice. You need a specialized support system to ensure that any medication you are taking is both safe and appropriate for your specific medical history. Navigating the divide between FDA-approved GLP-1s and compounded alternatives requires a multidisciplinary approach.

If you are currently using or considering these medications, here are the three types of local professionals Consider engage with to ensure your safety:

Board-Certified Obesity Medicine Physicians

Look for providers who are specifically certified in obesity medicine rather than general practitioners. You seek a professional who can provide a clinical rationale for choosing a compounded version over a brand-name drug and who can monitor your metabolic markers with precision. Ensure they are affiliated with recognized medical institutions and can explain the specific risks associated with non-FDA-approved agonists.

Licensed Compounding Pharmacists

Not all pharmacies are created equal. If you are using a compounded medication, you should work with a licensed pharmacist who can provide a full disclosure of the ingredients being used. Inquire about their sourcing for the active pharmaceutical ingredients (API) and their quality control protocols. A reputable compounding pharmacist will be transparent about the differences between their formulation and the FDA-approved version.

Registered Dietitians Specializing in Metabolic Health

Medication is only one part of the equation. To avoid the “yo-yo” effect and manage the side effects often associated with GLP-1s, you need a dietitian who understands the pharmacological impact of these drugs on digestion and muscle mass. Look for those with credentials in metabolic health who can create a nutritional framework that complements your medical treatment.

Ready to locate trusted professionals? Browse our complete directory of top-rated obesity medicine experts in the san diego area today.